Fig 1: BSN-AS2 accelerated spinal OS progression in a SYTL2-dependent way. a qRT-PCR and western blot assays examined SYTL2 mRNA and protein levels. b, c CCK-8 and colony formation assays illustrated cell proliferation in different groups. d, e Flow cytometry analysis and TUNEL assay evaluated cell apoptosis in transfected U2OS cells. f, g Transwell assay observed cell migration and invasion in transfected cells. h The photos of tumor obtained from mice in differently transfected groups were taken. Tumor volume curve was depicted. i Tumor volume and weight were measured. **P < 0.01
Fig 2: MiR-654-3p targeted SYTL2 to regulate spinal OS progression. a StarBase showed SYTL2 and CLN8 were potentially targeted by miR-654-3p. b qRT-PCR indicated the expression of SYTL2 and CLN8 in spinal OS cells and hFOB cells. c, d qRT-PCR and western blot assays uncovered the mRNA and protein expressions of STYL2. e RIP assay manifested the enrichment of BSN-AS2, miR-654-3p and SYTL2 in anti-Ago2 group. f RNA pull down showed miR-654-3p could bind with SYTL2. g The expression of SYTL2 in spinal OS tissues and adjacent-normal tissues was measured by qRT-PCR (left); Pearson correlation analysis illustrated the correlation between SYTL2 and miR-654-3p/BSN-AS2 (middle and right). h The potential binding site for miR-654-3p and SYTL2 was exhibited. i Luciferase reporter assay illustrated miR-654-3p could target SYTL2 in spinal OS. j qRT-PCR and western blot assays detected the mRNA and protein expressions of SYTL2. k, l CCK-8 and colony formation assays showed cell proliferation when inhibiting SYTL2. m, n Flow cytometry analysis and TUNEL assay determined cell apoptosis in SYTL2 silenced cells. o, p Transwell assay demonstrated cell migration and invasion in response to SYTL2 attenuation. **P < 0.01
Supplier Page from Abcam for Anti-SYTL2/SLP2 antibody